You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameResveratrol
Accession NumberDB02709  (EXPT02968)
TypeSmall Molecule
GroupsExperimental, Investigational
DescriptionResveratrol (3,5,4'-trihydroxystilbene) is a polyphenolic phytoalexin. It is a stilbenoid, a derivate of stilbene, and is produced in plants with the help of the enzyme stilbene synthase. It exists as two structural isomers: cis-(Z) and trans-(E), with the trans-isomer shown in the top image. The trans- form can undergo isomerisation to the cis- form when heated or exposed to ultraviolet irradiation. In a 2004 issue of Science, Dr. Sinclair of Harvard University said resveratrol is not an easy molecule to protect from oxidation. It has been claimed that it is readily degraded by exposure to light, heat, and oxygen. However, studies find that Trans-resveratrol undergoes negligible oxidation in normal atmosphere at room temperature. [Wikipedia]
Structure
Thumb
Synonyms
(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol
(E)-5-(p-Hydroxystyryl)resorcinol
(E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol
(E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol
(E)-resveratrol
3,4',5-Stilbenetriol
3,4',5-trihydroxy-stilbene
3,4',5-Trihydroxystilbene
trans-3,4',5-trihydroxystilbene
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Co-veratrolHome Aide Diagnostics, Inc.
SaltsNot Available
Categories
UNIIQ369O8926L
CAS number501-36-0
WeightAverage: 228.2433
Monoisotopic: 228.07864425
Chemical FormulaC14H12O3
InChI KeyLUKBXSAWLPMMSZ-OWOJBTEDSA-N
InChI
InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+
IUPAC Name
5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol
SMILES
OC1=CC=C(\C=C\C2=CC(O)=CC(O)=C2)C=C1
Pharmacology
IndicationBeing investigated for the treatment of Herpes labialis infections (cold sores).
Structured Indications Not Available
PharmacodynamicsResveratrol, a phytoalexin, has been found to inhibit herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) replication in a dose-dependent, reversible manner, although this is only one of its many pharmaceutical properties. In some countries where there is higher consumption of red wine, there appears to be a lower incidence of heart disease. Other benefits of resveratrol include its anti-inflammatory and antioxidant effects. In preclinical studies, Resveratrol has been found to have potential anticancer properties.
Mechanism of actionResveratrol suppresses NF-kappaB (NF-kappaB) activation in HSV infected cells. Reports have indicated that HSV activates NF-kappaB during productive infection and this may be an essential aspect of its replication scheme [PMID: 9705914].
TargetKindPharmacological actionActionsOrganismUniProt ID
Ribosyldihydronicotinamide dehydrogenase [quinone]ProteinunknownNot AvailableHumanP16083 details
Casein kinase II subunit alphaProteinunknownNot AvailableHumanP68400 details
Prostaglandin G/H synthase 1Proteinunknown
inhibitor
HumanP23219 details
Prostaglandin G/H synthase 2Proteinunknown
inhibitor
HumanP35354 details
Related Articles
AbsorptionHigh absorption but very low bioavailability.
Volume of distributionNot Available
Protein bindingStrong affinity towards protein binding.
Metabolism

Hepatic. Rapidly metabolized and excreted.

SubstrateEnzymesProduct
Resveratrol
piceatannol (3,5,3',4'-tetrahydroxystilbene)Details
Resveratrol
tetrahydroxystilbene M1Details
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Resveratrol is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Resveratrol is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Resveratrol is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Resveratrol is combined with 5-androstenedione.Experimental, Illicit
AbciximabResveratrol may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Resveratrol can be increased when it is combined with Abiraterone.Approved
AcebutololResveratrol may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Resveratrol is combined with Aceclofenac.Approved
AcenocoumarolResveratrol may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Acetovanillone.Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Resveratrol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinResveratrol may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Resveratrol.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Alendronic acid.Approved
AliskirenResveratrol may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololResveratrol may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Resveratrol.Approved, Investigational
AlteplaseResveratrol may increase the anticoagulant activities of Alteplase.Approved
ALX-0081Resveratrol may increase the anticoagulant activities of ALX-0081.Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Amcinonide.Approved
AmikacinResveratrol may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideResveratrol may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Aminosalicylic Acid.Approved
AmrubicinResveratrol may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AnagrelideResveratrol may increase the anticoagulant activities of Anagrelide.Approved
AncrodResveratrol may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Resveratrol is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Resveratrol is combined with Anisodamine.Investigational
AnistreplaseResveratrol may increase the anticoagulant activities of Anistreplase.Approved
annamycinResveratrol may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Resveratrol.Approved
Antithrombin III humanResveratrol may increase the anticoagulant activities of Antithrombin III human.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Resveratrol.Investigational
Aop200704Resveratrol may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanThe risk or severity of adverse effects can be increased when Resveratrol is combined with Apixaban.Approved
ApramycinResveratrol may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Resveratrol is combined with Apremilast.Approved, Investigational
ArbekacinResveratrol may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinResveratrol may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanResveratrol may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololResveratrol may decrease the antihypertensive activities of Arotinolol.Approved
AstaxanthinResveratrol may increase the anticoagulant activities of Astaxanthin.Investigational
AtenololResveratrol may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Resveratrol.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Resveratrol.Approved
AzithromycinThe metabolism of Resveratrol can be decreased when combined with Azithromycin.Approved
BalsalazideResveratrol may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BatroxobinResveratrol may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminResveratrol may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololResveratrol may decrease the antihypertensive activities of Befunolol.Experimental
BemiparinResveratrol may increase the anticoagulant activities of Bemiparin.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Resveratrol.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Resveratrol.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Resveratrol is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Resveratrol.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Betamethasone.Approved, Vet Approved
BetaxololResveratrol may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Betulinic Acid.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Resveratrol.Approved, Investigational
BevantololResveratrol may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Resveratrol.Approved, Investigational
BisoprololResveratrol may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinResveratrol may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololResveratrol may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Resveratrol can be decreased when combined with Bortezomib.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Resveratrol.Approved
BucillamineThe risk or severity of adverse effects can be increased when Resveratrol is combined with Bucillamine.Investigational
BucindololResveratrol may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Budesonide.Approved
BufuralolResveratrol may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideResveratrol may decrease the diuretic activities of Bumetanide.Approved
BupranololResveratrol may decrease the antihypertensive activities of Bupranolol.Approved
ButylphthalideResveratrol may increase the antiplatelet activities of Butylphthalide.Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Resveratrol.Approved
CaffeineThe metabolism of Resveratrol can be decreased when combined with Caffeine.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Resveratrol.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Resveratrol.Experimental
CangrelorResveratrol may increase the anticoagulant activities of Cangrelor.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Resveratrol.Approved
CarbamazepineThe metabolism of Resveratrol can be increased when combined with Carbamazepine.Approved, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Resveratrol.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Resveratrol.Approved, Vet Approved, Withdrawn
CarteololResveratrol may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolResveratrol may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Resveratrol.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Resveratrol is combined with Celecoxib.Approved, Investigational
CeliprololResveratrol may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinResveratrol may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Resveratrol.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Resveratrol.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Resveratrol.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Resveratrol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Resveratrol.Approved
CilostazolResveratrol may increase the anticoagulant activities of Cilostazol.Approved
CinoxacinResveratrol may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinResveratrol may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CitalopramThe metabolism of Resveratrol can be decreased when combined with Citalopram.Approved
Citric AcidResveratrol may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Clonixin.Approved
ClopidogrelResveratrol may increase the anticoagulant activities of Clopidogrel.Approved, Nutraceutical
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Resveratrol.Vet Approved
ClotrimazoleThe metabolism of Resveratrol can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Resveratrol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Resveratrol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CollagenaseThe risk or severity of adverse effects can be increased when Resveratrol is combined with Collagenase.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Resveratrol is combined with Curcumin.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Resveratrol.Approved, Investigational
CyclosporineResveratrol may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Resveratrol can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when Resveratrol is combined with D-Limonene.Investigational
Dabigatran etexilateResveratrol may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinResveratrol may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidResveratrol may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DasatinibDasatinib may increase the anticoagulant activities of Resveratrol.Approved, Investigational
DaunorubicinResveratrol may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Resveratrol is combined with Deferasirox.Approved, Investigational
DefibrotideResveratrol may increase the anticoagulant activities of Defibrotide.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Resveratrol is combined with dehydroepiandrosterone sulfate.Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Deoxycholic Acid.Approved
dersalazineThe risk or severity of adverse effects can be increased when Resveratrol is combined with dersalazine.Investigational
DesirudinResveratrol may increase the anticoagulant activities of Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Resveratrol.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Desmopressin.Approved
DesmoteplaseResveratrol may increase the anticoagulant activities of Desmoteplase.Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Resveratrol.Approved
DextranResveratrol may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Resveratrol may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Resveratrol may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Resveratrol may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Resveratrol.Approved, Vet Approved
DicoumarolResveratrol may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Resveratrol is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Difluprednate.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Resveratrol.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Resveratrol.Approved
DihydrostreptomycinResveratrol may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Resveratrol.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Resveratrol.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Resveratrol.Approved
DipyridamoleResveratrol may increase the anticoagulant activities of Dipyridamole.Approved
DitazoleResveratrol may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Resveratrol.Approved, Investigational
DoxorubicinResveratrol may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneResveratrol may increase the hyperkalemic activities of Drospirenone.Approved
Drotrecogin alfaResveratrol may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when Resveratrol is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Resveratrol is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Resveratrol is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Resveratrol is combined with Ebselen.Investigational
Edetic AcidResveratrol may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanResveratrol may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Resveratrol.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Resveratrol.Approved
EnoxacinResveratrol may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinResveratrol may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineEpinastine may increase the antiplatelet activities of Resveratrol.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Resveratrol is combined with Epirizole.Approved
EpirubicinResveratrol may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneResveratrol may decrease the antihypertensive activities of Eplerenone.Approved
eplivanserineResveratrol may increase the anticoagulant activities of eplivanserine.Investigational
EpoprostenolEpoprostenol may increase the antiplatelet activities of Resveratrol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Resveratrol.Approved
EptifibatideResveratrol may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Resveratrol is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Equilin.Approved
EsmololResveratrol may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Estrone sulfate.Approved
Etacrynic acidResveratrol may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Resveratrol.Approved, Investigational
Ethyl biscoumacetateResveratrol may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Resveratrol is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Resveratrol is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Resveratrol is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Resveratrol is combined with exisulind.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Resveratrol.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Resveratrol.Vet Approved
FibrinolysinResveratrol may increase the anticoagulant activities of Fibrinolysin.Approved
FleroxacinResveratrol may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Resveratrol.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Resveratrol is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fludrocortisone.Approved
FluindioneResveratrol may increase the anticoagulant activities of Fluindione.Investigational
FlumequineResveratrol may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Resveratrol.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Resveratrol.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Resveratrol can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Resveratrol.Approved, Nutraceutical, Vet Approved
FondaparinuxResveratrol may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumResveratrol may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Resveratrol.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Resveratrol.Approved
FramycetinResveratrol may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideResveratrol may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateResveratrol may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinResveratrol may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinResveratrol may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Resveratrol.Approved, Withdrawn
GemifloxacinResveratrol may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinResveratrol may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinResveratrol may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AResveratrol may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GlucosamineGlucosamine may increase the antiplatelet activities of Resveratrol.Approved
GrepafloxacinResveratrol may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Resveratrol is combined with HE3286.Investigational
HeparinResveratrol may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineResveratrol may increase the anticoagulant activities of Higenamine.Investigational
HirulogResveratrol may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Resveratrol is combined with HMPL-004.Investigational
HydralazineResveratrol may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Resveratrol.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Resveratrol.Approved
Hygromycin BResveratrol may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Ibandronate.Approved, Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Resveratrol is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Resveratrol.Approved
IbudilastResveratrol may increase the antiplatelet activities of Ibudilast.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Resveratrol.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Resveratrol is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Resveratrol is combined with Icatibant.Approved
Icosapent ethylResveratrol may increase the antiplatelet activities of Icosapent ethyl.Approved, Nutraceutical
IdarubicinResveratrol may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxResveratrol may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilResveratrol may increase the antiplatelet activities of Ifenprodil.Approved, Withdrawn
IloprostIloprost may increase the antiplatelet activities of Resveratrol.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Resveratrol.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Resveratrol.Approved
IndenololResveratrol may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenResveratrol may increase the anticoagulant activities of Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Resveratrol.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Resveratrol is combined with Indoprofen.Withdrawn
INNO-206Resveratrol may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Resveratrol.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Resveratrol is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Resveratrol is combined with Istaroxime.Investigational
KanamycinResveratrol may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
Kct 0809Resveratrol may increase the anticoagulant activities of Kct 0809.Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Kebuzone.Experimental
KetanserinResveratrol may increase the antiplatelet activities of Ketanserin.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Resveratrol.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Resveratrol.Approved
LabetalolResveratrol may decrease the antihypertensive activities of Labetalol.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Resveratrol.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Resveratrol.Approved, Investigational
LepirudinResveratrol may increase the anticoagulant activities of Lepirudin.Approved
LevobunololResveratrol may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinResveratrol may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LidocaineThe metabolism of Resveratrol can be decreased when combined with Lidocaine.Approved, Vet Approved
LimaprostLimaprost may increase the antiplatelet activities of Resveratrol.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Resveratrol.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Resveratrol is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Resveratrol.Approved
LomefloxacinResveratrol may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Resveratrol is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Resveratrol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Resveratrol is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Resveratrol.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Resveratrol is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Resveratrol.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Resveratrol.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Resveratrol.Approved
ME-609The risk or severity of adverse effects can be increased when Resveratrol is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Resveratrol.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Resveratrol.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Resveratrol.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Resveratrol is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Resveratrol is combined with Metamizole.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Resveratrol.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Resveratrol.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Methylprednisolone.Approved, Vet Approved
MetipranololResveratrol may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Resveratrol.Approved
MetoprololResveratrol may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideResveratrol may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MexiletineThe metabolism of Resveratrol can be decreased when combined with Mexiletine.Approved
MilrinoneMilrinone may increase the antiplatelet activities of Resveratrol.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Resveratrol.Approved
MizoribineThe risk or severity of adverse effects can be increased when Resveratrol is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Resveratrol.Approved
MometasoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Resveratrol.Approved
MoxifloxacinResveratrol may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Resveratrol.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Resveratrol.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Nabumetone.Approved
NadololResveratrol may decrease the antihypertensive activities of Nadolol.Approved
NadroparinResveratrol may increase the anticoagulant activities of Nadroparin.Approved
NafamostatResveratrol may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Resveratrol.Approved
NaftopidilResveratrol may increase the antiplatelet activities of Naftopidil.Investigational
Nalidixic AcidResveratrol may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Resveratrol.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Resveratrol is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Resveratrol is combined with NCX 4016.Investigational
NeamineResveratrol may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinResveratrol may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinResveratrol may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Resveratrol is combined with Nepafenac.Approved
NetilmicinResveratrol may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NevirapineThe metabolism of Resveratrol can be decreased when combined with Nevirapine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Nitroaspirin.Investigational
NorfloxacinResveratrol may increase the neuroexcitatory activities of Norfloxacin.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Resveratrol is combined with Obinutuzumab.Approved
OfloxacinResveratrol may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Resveratrol.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Resveratrol.Approved
OlsalazineResveratrol may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Resveratrol.Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Resveratrol.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Resveratrol can be decreased when it is combined with Osimertinib.Approved
OtamixabanResveratrol may increase the anticoagulant activities of Otamixaban.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Resveratrol.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Resveratrol.Approved
OxprenololResveratrol may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Oxyphenbutazone.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Resveratrol.Approved, Vet Approved
PamidronateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Resveratrol is combined with Parecoxib.Approved
ParnaparinResveratrol may increase the anticoagulant activities of Parnaparin.Approved
ParomomycinResveratrol may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinResveratrol may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinResveratrol may increase the neuroexcitatory activities of Pefloxacin.Approved
Peginterferon alfa-2bThe serum concentration of Resveratrol can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololResveratrol may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Resveratrol.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Resveratrol.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Resveratrol.Approved
PhenindioneResveratrol may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Resveratrol can be increased when combined with Phenobarbital.Approved
PhenprocoumonResveratrol may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Resveratrol.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Resveratrol.Approved, Investigational
PindololResveratrol may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinResveratrol may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideResveratrol may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Resveratrol.Approved, Investigational
PlasminResveratrol may increase the anticoagulant activities of Plasmin.Investigational
PlicamycinResveratrol may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Resveratrol.Approved
PractololResveratrol may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Resveratrol.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Prasterone.Approved, Nutraceutical
PrasugrelResveratrol may increase the anticoagulant activities of Prasugrel.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Pregnenolone.Experimental
PrimidoneThe metabolism of Resveratrol can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Resveratrol can be increased when it is combined with Probenecid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Propacetamol.Approved
PropranololResveratrol may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Resveratrol.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Resveratrol.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Resveratrol.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Resveratrol.Vet Approved
Protein CResveratrol may increase the anticoagulant activities of Protein C.Approved
Protein S humanResveratrol may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeResveratrol may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinResveratrol may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Resveratrol is combined with PTC299.Investigational
PuromycinResveratrol may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Resveratrol.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Resveratrol.Approved
RamatrobanResveratrol may increase the antiplatelet activities of Ramatroban.Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Resveratrol.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Resveratrol.Approved
ReteplaseResveratrol may increase the anticoagulant activities of Reteplase.Approved
ReviparinResveratrol may increase the anticoagulant activities of Reviparin.Approved
RibostamycinResveratrol may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RidogrelRidogrel may increase the antiplatelet activities of Resveratrol.Approved
RifampicinThe metabolism of Resveratrol can be increased when combined with Rifampicin.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Risedronate.Approved, Investigational
RivaroxabanResveratrol may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Resveratrol is combined with Rofecoxib.Investigational, Withdrawn
RopiniroleThe metabolism of Resveratrol can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneResveratrol may increase the anticoagulant activities of Rosiglitazone.Approved, Investigational
RosoxacinResveratrol may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Resveratrol.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Resveratrol.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Resveratrol.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Resveratrol.Investigational
SCH-530348Resveratrol may increase the antiplatelet activities of SCH-530348.Investigational
SelexipagResveratrol may increase the anticoagulant activities of Selexipag.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Resveratrol is combined with Seratrodast.Approved, Investigational
SevofluraneSevoflurane may increase the antiplatelet activities of Resveratrol.Approved, Vet Approved
SimeprevirThe metabolism of Resveratrol can be decreased when combined with Simeprevir.Approved
SisomicinResveratrol may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SotalolResveratrol may decrease the antihypertensive activities of Sotalol.Approved
SP1049CResveratrol may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinResveratrol may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinResveratrol may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Resveratrol.Approved
SpironolactoneResveratrol may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Resveratrol is combined with SRT501.Investigational
StreptokinaseResveratrol may increase the anticoagulant activities of Streptokinase.Approved
StreptomycinResveratrol may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinResveratrol may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineResveratrol may increase the nephrotoxic activities of Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Resveratrol.Approved
SulodexideResveratrol may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Resveratrol.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Resveratrol.Approved, Withdrawn
TacrolimusResveratrol may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Resveratrol.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Resveratrol.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Resveratrol.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Resveratrol.Approved, Investigational
TemafloxacinResveratrol may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Resveratrol.Experimental, Investigational
TenecteplaseResveratrol may increase the anticoagulant activities of Tenecteplase.Approved
TenofovirThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Resveratrol.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tepoxalin.Vet Approved
TeriflunomideThe serum concentration of Resveratrol can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneResveratrol may increase the antiplatelet activities of Tesmilifene.Investigational
TheophyllineThe metabolism of Resveratrol can be decreased when combined with Theophylline.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Resveratrol.Approved
TicagrelorResveratrol may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineThe metabolism of Resveratrol can be decreased when combined with Ticlopidine.Approved
TiludronateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tiludronate.Approved, Vet Approved
TimololResveratrol may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tinoridine.Investigational
TinzaparinResveratrol may increase the anticoagulant activities of Tinzaparin.Approved
TipranavirTipranavir may increase the antiplatelet activities of Resveratrol.Approved, Investigational
TirofibanResveratrol may increase the anticoagulant activities of Tirofiban.Approved
TixocortolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tixocortol.Approved
TobramycinResveratrol may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Resveratrol.Approved
TorasemideResveratrol may decrease the diuretic activities of Torasemide.Approved
TositumomabThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tositumomab.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Resveratrol.Approved
TranilastThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tranilast.Approved, Investigational
TrapidilResveratrol may increase the antiplatelet activities of Trapidil.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Resveratrol.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Resveratrol.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Resveratrol.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Triamcinolone.Approved, Vet Approved
TriamtereneResveratrol may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Resveratrol.Approved, Vet Approved
TriflusalResveratrol may increase the anticoagulant activities of Triflusal.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Resveratrol.Approved
TrovafloxacinResveratrol may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Resveratrol.Approved
UrokinaseResveratrol may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Resveratrol is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinResveratrol may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Resveratrol.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Resveratrol.Approved
VemurafenibThe serum concentration of Resveratrol can be increased when it is combined with Vemurafenib.Approved
Vitamin EVitamin E may increase the antiplatelet activities of Resveratrol.Approved, Nutraceutical, Vet Approved
VorapaxarResveratrol may increase the anticoagulant activities of Vorapaxar.Approved
WarfarinResveratrol may increase the anticoagulant activities of Warfarin.Approved
XimelagatranResveratrol may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Resveratrol may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Resveratrol is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Resveratrol.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Resveratrol is combined with Zomepirac.Withdrawn
ZorubicinResveratrol may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food InteractionsNot Available
References
Synthesis Reference

Philippe Jeandet, Roger Bessis, Marielle Adrian, Jean-Claude Yvin, Jean-Marie Joubert, “Use of aluminium chloride as a resveratrol synthesis elicitor.” U.S. Patent US6080701, issued August, 1991.

US6080701
General References
  1. Farina A, Ferranti C, Marra C: An improved synthesis of resveratrol. Nat Prod Res. 2006 Mar;20(3):247-52. [PubMed:16401555 ]
  2. Renaud S, Ruf JC: The French paradox: vegetables or wine. Circulation. 1994 Dec;90(6):3118-9. [PubMed:7994864 ]
  3. Wang Y, Catana F, Yang Y, Roderick R, van Breemen RB: An LC-MS method for analyzing total resveratrol in grape juice, cranberry juice, and in wine. J Agric Food Chem. 2002 Jan 30;50(3):431-5. [PubMed:11804508 ]
  4. Lyons MM, Yu C, Toma RB, Cho SY, Reiboldt W, Lee J, van Breemen RB: Resveratrol in raw and baked blueberries and bilberries. J Agric Food Chem. 2003 Sep 24;51(20):5867-70. [PubMed:13129286 ]
  5. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK: High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004 Dec;32(12):1377-82. Epub 2004 Aug 27. [PubMed:15333514 ]
  6. Csaki C, Keshishzadeh N, Fischer K, Shakibaei M: Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro. Biochem Pharmacol. 2008 Feb 1;75(3):677-87. Epub 2007 Sep 18. [PubMed:17959154 ]
  7. Docherty JJ, Fu MM, Stiffler BS, Limperos RJ, Pokabla CM, DeLucia AL: Resveratrol inhibition of herpes simplex virus replication. Antiviral Res. 1999 Oct;43(3):145-55. [PubMed:10551373 ]
  8. N' soukpoe-Kossi CN, St-Louis C, Beauregard M, Subirade M, Carpentier R, Hotchandani S, Tajmir-Riahi HA: Resveratrol binding to human serum albumin. J Biomol Struct Dyn. 2006 Dec;24(3):277-83. [PubMed:17054386 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSDownload (16.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9952
Blood Brain Barrier+0.59
Caco-2 permeable+0.8915
P-glycoprotein substrateNon-substrate0.6501
P-glycoprotein inhibitor INon-inhibitor0.9266
P-glycoprotein inhibitor IINon-inhibitor0.9612
Renal organic cation transporterNon-inhibitor0.8634
CYP450 2C9 substrateNon-substrate0.7519
CYP450 2D6 substrateNon-substrate0.9288
CYP450 3A4 substrateNon-substrate0.7143
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorInhibitor0.7068
CYP450 2D6 inhibitorNon-inhibitor0.9226
CYP450 2C19 inhibitorInhibitor0.8052
CYP450 3A4 inhibitorInhibitor0.7539
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8559
Ames testNon AMES toxic0.8407
CarcinogenicityNon-carcinogens0.7825
BiodegradationNot ready biodegradable0.8499
Rat acute toxicity1.6791 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8933
hERG inhibition (predictor II)Non-inhibitor0.9462
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
CapsuleOral
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point254 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.0688 mg/mLALOGPS
logP2.57ALOGPS
logP3.4ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)8.49ChemAxon
pKa (Strongest Basic)-6.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area60.69 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity67.46 m3·mol-1ChemAxon
Polarizability24.55 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
GC-MSGC-MS Spectrum - GC-MS (3 TMS)splash10-0006-1853900000-4919511a11ec24935434View in MoNA
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassStilbenes
Sub ClassNot Available
Direct ParentStilbenes
Alternative Parents
Substituents
  • Stilbene
  • Styrene
  • Resorcinol
  • Phenol
  • Benzenoid
  • Monocyclic benzene moiety
  • Hydrocarbon derivative
  • Organooxygen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Nadph dehydrogenase (quinone) activity
Specific Function:
The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinones involved in detoxification pathways as well as in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthesis.
Gene Name:
NQO2
Uniprot ID:
P16083
Molecular Weight:
25918.4 Da
References
  1. Buryanovskyy L, Fu Y, Boyd M, Ma Y, Hsieh TC, Wu JM, Zhang Z: Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry. 2004 Sep 14;43(36):11417-26. [PubMed:15350128 ]
  2. Wang Z, Hsieh TC, Zhang Z, Ma Y, Wu JM: Identification and purification of resveratrol targeting proteins using immobilized resveratrol affinity chromatography. Biochem Biophys Res Commun. 2004 Oct 22;323(3):743-9. [PubMed:15381063 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein serine/threonine kinase activity
Specific Function:
Catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine. Regulates numerous cellular processes, such as cell cycle progression, apoptosis and transcription, as well as viral infection. May act as a regulatory node which integrates and coor...
Gene Name:
CSNK2A1
Uniprot ID:
P68400
Molecular Weight:
45143.25 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Piver B, Fer M, Vitrac X, Merillon JM, Dreano Y, Berthou F, Lucas D: Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochem Pharmacol. 2004 Aug 15;68(4):773-82. [PubMed:15276085 ]
  2. Chang TK, Chen J, Lee WB: Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther. 2001 Dec;299(3):874-82. [PubMed:11714871 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Chang TK, Chen J, Lee WB: Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther. 2001 Dec;299(3):874-82. [PubMed:11714871 ]
  2. Piver B, Fer M, Vitrac X, Merillon JM, Dreano Y, Berthou F, Lucas D: Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochem Pharmacol. 2004 Aug 15;68(4):773-82. [PubMed:15276085 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Chang TK, Chen J, Lee WB: Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther. 2001 Dec;299(3):874-82. [PubMed:11714871 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Chow HH, Garland LL, Hsu CH, Vining DR, Chew WM, Miller JA, Perloff M, Crowell JA, Alberts DS: Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila). 2010 Sep;3(9):1168-75. doi: 10.1158/1940-6207.CAPR-09-0155. Epub 2010 Aug 17. [PubMed:20716633 ]
  2. Piver B, Berthou F, Dreano Y, Lucas D: Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett. 2001 Dec 15;125(1-3):83-91. [PubMed:11701226 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Identical protein binding
Specific Function:
Thyroid hormone-binding protein. Probably transports thyroxine from the bloodstream to the brain.
Gene Name:
TTR
Uniprot ID:
P02766
Molecular Weight:
15886.88 Da
References
  1. Commodari F, Khiat A, Ibrahimi S, Brizius AR, Kalkstein N: Comparison of the phytoestrogen trans-resveratrol (3,4',5-trihydroxystilbene) structures from x-ray diffraction and solution NMR. Magn Reson Chem. 2005 Jul;43(7):567-72. [PubMed:15809979 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23